Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 20/20 | 0.68 |
| ▸ | F2 | P00734 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657062 | 1.00 | F12 (0.68) | F12F2 | |
| SCHEMBL19657071 | 0.86 | F12 (0.69) | F12F2 | |
| SCHEMBL21084630 | 0.86 | F12 (0.69) | F12F2 | |
| SCHEMBL19657068 | 0.86 | F12 (0.69) | F12F2 | |
| SCHEMBL21084638 | 0.85 | F12 (0.67) | F12F2 | |
| SCHEMBL19657072 | 0.85 | F12 (0.67) | F12F2 | |
| SCHEMBL19657066 | 0.85 | F12 (0.67) | F12F2 | |
| SCHEMBL21084678 | 0.82 | F12 (0.73) | F12F2 | |
| SCHEMBL19657053 | 0.82 | F12 (0.76) | F12F2 | |
| SCHEMBL19656999 | 0.82 | F12 (0.73) | F12F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI2, IL4I1, TFPI | F12 16/4885F2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.